Gin Thomas J, Surendran Sujan A, Rogers Sophie L, Lim Lyndell L
Centre for Eye Research Australia, Melbourne, Victoria, Australia.
Ophthalmology, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.
Clin Exp Ophthalmol. 2025 Aug;53(6):627-636. doi: 10.1111/ceo.14538. Epub 2025 Apr 20.
To identify predictive factors of uveitis refractory to treatment in initial-onset acute Vogt-Koyanagi-Harada disease.
This was a retrospective chart review of patients with initial-onset acute Vogt-Koyanagi-Harada disease presenting to the Royal Victorian Eye and Ear Hospital, Melbourne, Australia between July 2001 and March 2023 inclusive. Factors predictive of uveitis refractory to treatment were determined using logistic regression models with, and without, adjustment for initial use of intravenous methylprednisolone.
Thirty-eight patients with initial-onset acute Vogt-Koyanagi-Harada were included, 27 of whom received initial intravenous corticosteroids (71%) and 23 met the criteria for uveitis refractory to treatment (61%). Comparing those who received intravenous corticosteroids to those who did not, the incidence of complications, time-to-quiescence, time-to-relapse, time-to-low dose corticosteroid or corticosteroid-sparing control of inflammation and time-to-remission were not statistically different (all p > 0.164). Factors at onset of treatment that were predictive for uveitis refractory to treatment included greater anterior chamber inflammation (p = 0.008), greater vitreous inflammation (p = 0.015), the absence of bacillary layer detachments on macular optical coherence tomography (p = 0.010) and commencement of systemic steroid therapy 1 week or longer after ocular symptom onset (p = 0.013). Absence of intravenous corticosteroids as initial therapy was not a statistically significant predictive factor for refractory disease (p = 0.802).
Delayed commencement of systemic steroid therapy and higher severity of intraocular inflammation at presentation are predictive of initial-onset acute Vogt-Koyanagi-Harada disease evolving into disease refractory to treatment.
确定初发性急性Vogt-小柳-原田病中对治疗难治性葡萄膜炎的预测因素。
这是一项对2001年7月至2023年3月(含)期间就诊于澳大利亚墨尔本皇家维多利亚眼耳医院的初发性急性Vogt-小柳-原田病患者的回顾性病历审查。使用逻辑回归模型确定对治疗难治性葡萄膜炎的预测因素,模型分别进行了和未进行静脉注射甲基泼尼松龙初始使用情况的调整。
纳入了38例初发性急性Vogt-小柳-原田病患者,其中27例接受了初始静脉注射皮质类固醇(71%),23例符合治疗难治性葡萄膜炎的标准(61%)。将接受静脉注射皮质类固醇的患者与未接受的患者进行比较,并发症发生率、静止时间、复发时间、低剂量皮质类固醇或皮质类固醇节省控制炎症时间以及缓解时间在统计学上无差异(所有p> 0.164)。治疗开始时预测对治疗难治性葡萄膜炎的因素包括前房炎症更严重(p= 0.008)、玻璃体炎症更严重(p= 0.015)、黄斑光学相干断层扫描上无视网膜色素上皮脱离(p= 0.010)以及眼部症状出现后1周或更长时间开始全身类固醇治疗(p= 0.013)。初始治疗未使用静脉注射皮质类固醇不是难治性疾病的统计学显著预测因素(p= 0.802)。
全身类固醇治疗开始延迟以及就诊时眼内炎症严重程度较高可预测初发性急性Vogt-小柳-原田病发展为难治性疾病。